MeiraGTx | Sustainability Performance
Clinical-stage gene therapy company focused on inherited retinal diseases and other conditions.
2015
United Kingdom
201 - 500 employees
Biotechnology
$25M - 100M in revenue
N/A in profitability
Sustainability Ranking & Industry Benchmark
#6595
Overall#928
in United Kingdom#127
in BiotechnologySustainability Maturity
Sustainability Intent
Overview
Governance
TargetsESG scores and exclusionsFinancial Data
Business performanceCapital & innovationAnalyst projections
Market cap
Revenue
R&D intensity
Controversy level
Powered by illuminem
Market cap
Revenue
EBITDA
Operating margin
Revenue & EBITDA
$81.0MFY2025 revenue
Total Annual
Revenue & EBITDA
($ B)
Annual revenue
EBITDA
3 year change
Margin trends
Margin as % of revenue
Gross margin
Operating margin
Net margin
Powered by illuminem
Free cashflow
Capex
Debt/equity ratio
R&D intensity
159.3%FY2025
R&D as % of revenue
R&D as % of revenue
Industry benchmark
Powered by illuminem
Return on invested capital
-160.0%FY2026
Return on invested capital (ROIC)
Industry benchmark
Powered by illuminem
Analyst revenue estimates & actuals
Analyst consensus vs actuals
($ B)
Actual revenue
Consensus estimates
Estimate only
0.0
▼ 65.3%
0.0
▲ 146.4%
0.1
▲ 672.3%
0.6
2030Powered by illuminem
Environmental policy coverage
Carbon reduction policy
Not available
Human rights policy
Not available
Recycling policy
Not available
Workplace health & safety policy
Available
55%
Independent Directors
6 out of 11 incl. management
Overall score
74
Environment
80
Social
75
Governance
66
Exclusion screening
Adult content
Not available
Alcoholic
Not available
Animal testing
Available
Firearms
Not available
Tobacco
Not available
Gambling
Not available
Nuclear
Not available
